AstraZeneca (AZN) Price Target Raised to GBX 6,000

AstraZeneca (LON:AZN) had its target price lifted by Berenberg Bank from GBX 5,800 ($81.32) to GBX 6,000 ($84.13) in a report released on Thursday morning. Berenberg Bank currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other reports. UBS Group set a GBX 4,550 ($63.80) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Monday, October 23rd. Deutsche Bank restated a buy rating and set a GBX 5,600 ($78.52) price objective on shares of AstraZeneca in a research report on Wednesday, October 11th. JPMorgan Chase & Co. set a GBX 5,500 ($77.12) price objective on AstraZeneca and gave the stock a buy rating in a research report on Thursday, January 4th. Morgan Stanley restated an equal weight rating and set a GBX 5,000 ($70.11) price objective on shares of AstraZeneca in a research report on Friday, December 1st. Finally, Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Hold and a consensus target price of GBX 5,211.65 ($73.07).

Shares of AstraZeneca (AZN) traded down GBX 52 ($0.73) during midday trading on Thursday, reaching GBX 4,793 ($67.20). The company’s stock had a trading volume of 1,530,000 shares, compared to its average volume of 1,980,000. AstraZeneca has a 12-month low of GBX 4,260 ($59.73) and a 12-month high of GBX 5,520 ($77.40). The firm has a market cap of $60,560.00 and a price-to-earnings ratio of 2,819.41.

In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were bought at an average cost of GBX 4,846 ($67.95) per share, with a total value of £20,110.90 ($28,198.12).

TRADEMARK VIOLATION NOTICE: “AstraZeneca (AZN) Price Target Raised to GBX 6,000” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2018/02/09/astrazeneca-azn-price-target-raised-to-gbx-6000.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit